Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/Phase 2 Study of IMM01 Combined With Azacitidine in Patients With AML and MDS

Next Previous
X
Search
Trial Profile

Phase 1/Phase 2 Study of IMM01 Combined With Azacitidine in Patients With AML and MDS

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; IMM-01 ImmuneOnco Biopharma (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors ImmuneOnco Biopharma

    • Most Recent Events

    • 04 Jun 2024 Results (n=57, data cut off: Dec 22, 2023) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 12 Dec 2023 Results ( August 4, 2022 and July 7, 2023, n=24) assessing safety and efficacy of IMM01 , presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results evaluating safety and efficacy of IMM01 in combination with AZA as the first-line treatment for patients with untreated higher-risk MDS,presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top